14 Recruiting Studies Using Enasidenib
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Enasidenib
Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation
📍 Children's Hospital of Alabama — Birmingham, Alabama
Recurrent Acute Myeloid Leukemia
View Study & Checklist ➔CPX-351 Plus Enasidenib for Relapsed AML
📍 UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California
Recurrent Acute Myeloid Leukemia
View Study & Checklist ➔A Study of Enasidenib in People With T-Cell Lymphoma
📍 Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
T-cell Lymphoma
View Study & Checklist ➔IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
📍 University of Colorado — Aurora, Colorado
Acute Myeloid Leukemia
View Study & Checklist ➔Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
Metastatic Chondrosarcoma
View Study & Checklist ➔Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
📍 Banner University Medical Center - Tucson — Tucson, Arizona
Acute Myeloid Leukemia
View Study & Checklist ➔Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
📍 Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
Acute Myeloid Leukemia
View Study & Checklist ➔Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
📍 M D Anderson Cancer Center — Houston, Texas
Acute Bilineal Leukemia
View Study & Checklist ➔Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission
📍 M D Anderson Cancer Center — Houston, Texas
Acute Myeloid Leukemia
View Study & Checklist ➔Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial
📍 Washington University School of Medicine — St Louis, Missouri
Clonal Cytopenia of Undetermined Significance
View Study & Checklist ➔Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
📍 Alta Bates Summit Medical Center-Herrick Campus — Berkeley, California
Myelodysplastic Syndrome
View Study & Checklist ➔A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
📍 Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
Acute Myeloid Leukemia (AML)
View Study & Checklist ➔MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Acute Myeloid Leukemia
View Study & Checklist ➔Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
Acute Myeloid Leukemia
View Study & Checklist ➔